Phase II Evaluation of Cetuximab (C225) Combined With Induction Paclitaxel and Carboplatin Followed by C225, Paclitaxel, Carboplatin, and Radiation for Stage III/IV Operable Squamous Cancer of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 09 Jul 2014
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Paclitaxel
- Indications Head and neck cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Mar 2012 Planned end date Feb 2010 as reported by ClinicalTrials.gov.
- 30 Aug 2005 New trial record.